SEC INSIDER TRANSACTIONS
Edwards Lifesciences Corp (EW) Insider Transactions
Explore official ownership filings, with every record linked to its source.
EW · Edwards Lifesciences Corp
How to read this data ↗
Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 3 filings · fetched 2026-11-13T17:39:21Z
View six-calendar-month insider history →
Recent reported activity
Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.
| Transaction / filed | Reporting owner(s) | Code / security | Quantity | Price as filed | Ownership | Source |
|---|---|---|---|---|---|---|
| 2026-11-10Filed 2026-11-10 | Lippis Daniel J.Officer · CVP, TAVRFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: | M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 619D | 0 | Direct | Form 4 ↗0001225208-26-008802 |
| 2026-11-10Filed 2026-11-10 | Lippis Daniel J.Officer · CVP, TAVRFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1 | S Sale (market/private)Common Stock · Non-derivative | 619D | 104.25 | Direct | Form 4 ↗0001225208-26-008802 |
| 2026-11-10Filed 2026-11-10 | Lippis Daniel J.Officer · CVP, TAVRFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1 | M Exercise / conversionCommon Stock · Non-derivative | 619A | 72.68 | Direct | Form 4 ↗0001225208-26-008802 |
| 2026-11-09Filed 2026-11-09 | BOBO DONALD E JROfficer · CVP,Strategy/Corp DevelopmentFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: | M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 48,900D | 0 | Direct | Form 4 ↗0001225208-26-008779 |
| 2026-11-09Filed 2026-11-09 | BOBO DONALD E JROfficer · CVP,Strategy/Corp DevelopmentFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 48,900D | 103.0534 | Direct | Form 4 ↗0001225208-26-008779 |
| 2026-11-09Filed 2026-11-09 | BOBO DONALD E JROfficer · CVP,Strategy/Corp DevelopmentFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1 | M Exercise / conversionCommon Stock · Non-derivative | 48,900A | 72.68 | Direct | Form 4 ↗0001225208-26-008779 |
| 2026-11-09Filed 2026-11-09 | Zovighian Bernard JDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F4 | M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 23,100D | 0 | Direct | Form 4 ↗0001225208-26-008780 |
| 2026-11-09Filed 2026-11-09 | Zovighian Bernard JDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F3 | S Sale (market/private)Common Stock · Non-derivative | 13,916D | 102.7803 | Direct | Form 4 ↗0001225208-26-008780 |
| 2026-11-09Filed 2026-11-09 | Zovighian Bernard JDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 9,184D | 103.3851 | Direct | Form 4 ↗0001225208-26-008780 |
| 2026-11-09Filed 2026-11-09 | Zovighian Bernard JDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1 | M Exercise / conversionCommon Stock · Non-derivative | 23,100A | 72.68 | Direct | Form 4 ↗0001225208-26-008780 |
Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.